1 not yet recruiting, 1 recruiting. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Not yet recruiting 1, Recruiting 1 |
Follow Metabolism: new trials by email Literature Review of Metabolism trials Research Report on Metabolism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway Vericiguat 10 MG, Placebo, Insulin Sensitivity Test - Cardiovascular Diseases, Insulin Sensitivity/Resistance | Phase 2 | Not yet recruiting | University of Alabama at Birmingham | 200 | 2026-12-01 | 2026-01-23 |
| NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals Sacubitril, Valsartan 97-103 mg Oral Tablet, Valsartan 160 mg, Intravenous Glucose Tolerance Test - Diabetes Mellitus, Cardiovascular Diseases | Phase 2 | Recruiting | University of Alabama at Birmingham | 200 | 2020-08-15 | 2026-07-28 |
Cardiovascular Diseases (2) · Insulin Resistance (2) · Metabolic Diseases (2) · Diabetes Mellitus (1) · Obesity (1)
Glucose Metabolism Disorders (2) · Hyperinsulinism (2) · Nutritional and Metabolic Diseases (2) · Body Weight (1) · Endocrine System Diseases (1) · Nutrition Disorders (1) · Overnutrition (1) · Overweight (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Glucose Tolerance Test (1) · Tablets (1) · Valsartan (1) · sacubitril (1) · vericiguat (1)
University of Alabama at Birmingham (2)
United States (2)
PMID 25595796, PMID 27542885, PMID 28330649, PMID 31162140
R01HL163852 (1)